Peter A. Fasching
Artificial Intelligence · 2012–2022
A researcher in the Science corpus: 11 papers; trusts 42 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Artificial Intelligence — 26 citations into it
- Computer Vision and Pattern Recognition — 17 citations into it
- Model Architectures — 8 citations into it
- Medical & Health AI — 6 citations into it
Whom Peter A. Fasching trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
- Yoshua Bengio
- Geoffrey E. Hinton
- Alex Krizhevsky
- Yann LeCun
- Ilya Sutskever
- Kyunghyun Cho
- Volodymyr Mnih
- Dzmitry Bahdanau
- Ross B. Girshick
- Diederik P. Kingma
Papers from Peter A. Fasching's perspective
Ordered by how strongly the researchers Peter A. Fasching trusts endorse each paper. Same corpus, a different order for every researcher.
- ImageNet classification with deep convolutional neural networks
- Gradient-based learning applied to document recognition
- Attention is All you Need (Neural Information Processing Systems)
- Deep Residual Learning for Image Recognition (Computer Vision and Pattern Recognition)
- Going deeper with convolutions
- Adam: A Method for Stochastic Optimization (International Conference on Learning Representations)
- Long Short-Term Memory
- Neural Machine Translation by Jointly Learning to Align and Translate (International Conference on Learning Representations)
- ImageNet: A large-scale hierarchical image database
- Learning Multiple Layers of Features from Tiny Images
Their papers
- Explaining Therapy Predictions with Layer-Wise Relevance Propagation in Neural Networks (2018) — 79 citations
- Breast Cancer Risk Genes — Association Analysis in More than 113,000 Women (2021) — 858 citations
- Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. (2022) — 879 citations
- Pembrolizumab for Early Triple-Negative Breast Cancer. (2020) — 2,341 citations
- Trastuzumab Emtansine for Residual Invasive HER2‐Positive Breast Cancer (2019) — 2,069 citations
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. (2018) — 1,800 citations
- Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk (2015) — 842 citations
- Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. (2014) — 906 citations
- Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients (2014) — 604 citations
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. (2014) — 4,135 citations
- Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. (2012) — 2,412 citations